Compare RVLV & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | KLRA |
|---|---|---|
| Founded | 2003 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2018 | 2026 |
| Metric | RVLV | KLRA |
|---|---|---|
| Price | $18.78 | $13.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $30.31 | ★ $42.75 |
| AVG Volume (30 Days) | 819.5K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.64 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $14.43 | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | $30.27 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $9.76 |
| 52 Week High | $31.68 | $23.82 |
| Indicator | RVLV | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 30.19 | 54.48 |
| Support Level | $17.91 | $9.76 |
| Resistance Level | $23.98 | $13.83 |
| Average True Range (ATR) | 1.22 | 0.90 |
| MACD | -0.43 | 0.09 |
| Stochastic Oscillator | 13.46 | 72.08 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.